No Data
No Data
Hamilton Thorne Maintained at Buy at Stifel GMP on No Impact From U.S. IVF Actions; Price Target Kept at C$2.55
Stifel GMP on Friday maintained its buy rating on the shares of Hamilton Thorne (HTL.TO) and its C$2.55 price target as sees no impact on the assisted reproductive technologies company from opposition
Hamilton Thorne Q1 Loss Widens Even as Sales Increase
Hamilton Thorne (HTL.TO) reported a wider first-quarter loss on higher operating expenses, despite a 16% increase in sales. The company, which services the assisted reproductive technologies and cell
Hamilton Thorne to Announce Q1 2024 Financial Results and Hold Conference Call on May 14, 2024
BEVERLY, Mass. and TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX: HTL), a leading provider of precision instruments, laboratory equipment, consumables, software and services to
Hamilton Thorne Ltd.'s (TSE:HTL) Largest Shareholders Are Retail Investors With 51% Ownership, Institutions Own 33%
Hamilton Thorne Ltd. to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Beverly, Massachusetts--(Newsfile Corp. - April 10, 2024) - Hamilton Thorne Ltd. (TSX: HTL) (OTC Pink: HTLZF), Hamilton Thorne Ltd. a leading provider of precision instruments, laboratory equipment, c
Earnings Call Summary | HAMILTON THORNE LTD(HTLZF.US) Q4 2023 Earnings Conference
The following is a summary of the Hamilton Thorne Ltd. (HTLZF) Q4 2023 Earnings Call Transcript:Financial Performance:Hamilton Thorne experienced a solid financial year, with a 16% increase in annual